전립선암의 치료에서 간헐적 남성호르몬 차단요법의 효과: 주기별 변화 및 특징

Abstract

Purpose: The purpose of this study was to evaluate cycling change and characteristics of treatment in patients receiving intermittent androgen suppression (IAS). Materials and Methods: From May 1995 to April 2001, we retrospectively reviewed 28 cases of prostate cancer patients treated with IAS. Treatment was initiated with goserelin acetate with flutamide and continued until serum PSA nadir was observed. Medication was then withheld till the serum PSA increased to a predetermined level. This cycle of treatment and no-treatment was repeated until the regulation of PSA became androgen independent. Results: Patients have completed at least one, and up to four treatment cycles. Mean nadir serum PSA level was 0.69ng/ml, 0.70ng/ml, 1.15ng/ml, 2.64ng/ml for each cycle, and was reached within average 4.7 (2-8) months after beginning treatment. Patients spent an average of 42% of the time not receiving therapy, but the time off therapy decreased as the number of treatment cycles increased. In most cases, side effects related with androgen suppression was improved during off-treatment. Conclusions: IAS appears to be a possible treatment option in patients with prostate cancer. This approach could result in reduced toxicity and cost of treatment and affords an improved quality of life when the patient is off therapy. (Korean J Urol 2002; 43:386-390)